SCHEMBL16201992

SCHEMBL16201992

CO/N=C(\C)c1ccc(-n2ccc(C)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.44
OXTR P30559 3/20 0.39
AVPR1A P37288 3/20 0.39
AVPR2 P30518 2/20 0.39
MAPT P10636 4/20 0.39
RAB9A P51151 3/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
NPC1 O15118 2/20 0.38
HDAC4 P56524 1/20 0.38
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ATM Q13315 1/20 0.37
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
LMNA P02545 3/20 0.35
PTBP1 P26599 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16202010 0.78 LMNA (0.37) HTTMAPTL3MBTL1SMN1; SMN2LMNA
SCHEMBL18865614 0.76 NOTUM (0.47) MAPTALDH1A1KDM4EMGLLMAPK1
SCHEMBL18883071 0.76 NOTUM (0.47) MAPTALDH1A1KDM4EMGLLMAPK1
SCHEMBL12436877 0.76 HTT (0.54) HTTOXTRAVPR1AAVPR2MAPT
SCHEMBL15935403 0.75 ALDH1A1 (0.55) HTTOXTRAVPR1AAVPR2MAPT
SCHEMBL12750110 0.74 LMNA (0.48) HTTMAPTL3MBTL1SMN1; SMN2LMNA
SCHEMBL1770474 0.72 HTT (0.54) HTTOXTRAVPR1AAVPR2MAPT
SCHEMBL598042 0.72 HTT (0.53) HTTMAPTRAB9AALDH1A1KDM4E
SCHEMBL3657454 0.71 HTT (0.53) HTTOXTRAVPR1AAVPR2MAPT
SCHEMBL6624353 0.71 HTT (0.53) HTTOXTRAVPR1AAVPR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2016-09-01 US disclosed
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-26 US disclosed
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi BASF SE (DE) 2016-05-26 US disclosed
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-05 US disclosed
US-9271501-B2 Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors BASF SE (DE) 2016-03-01 US disclosed
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI SNX1, DPM1, SNU13 HTT 3148/4885OXTR 4870/4885AVPR1A 4875/4885
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI DPM1, CROCC, SNX1 HTT 2598/4885OXTR 4866/4885AVPR1A 4881/4885
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi DPM1, CROCC, SNX1 HTT 2598/4885OXTR 4866/4885AVPR1A 4881/4885
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB HTT 2375/4885OXTR 4801/4885AVPR1A 4871/4885
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB HTT 2375/4885OXTR 4801/4885AVPR1A 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.